Abbott Laboratories (ABT)

Abbott Laboratories Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	5,723	6,933	7,071	4,495	3,687
Depreciation & Amortization	3,243	3,267	3,538	3,327	3,014
Share-Based Compensation	644	685	640	546	519
Other Operating Activities	-2,349	-1,304	-716	-467	-1,084
Operating Cash Flow	7,261	9,581	10,533	7,901	6,136
Operating Cash Flow Growth	-24.21%	-9.04%	33.31%	28.76%	-2.60%
Capital Expenditures	-2,202	-1,777	-1,885	-2,177	-1,638
Acquisitions	-837	48	-53	16	-122
Change in Investments	-116	-33	-96	-73	-82
Other Investing Activities	22	22	26	19	27
Investing Cash Flow	-3,133	-1,740	-2,008	-2,215	-1,815
Dividends Paid	-3,556	-3,309	-3,202	-2,560	-2,270
Share Issuance / Repurchase	-1,060	-3,628	-2,044	-158	-420
Debt Issued / Paid	-2,475	-699	-248	-50	-1,599
Other Financing Activities	-	-	-	-11	-
Financing Cash Flow	-7,091	-7,636	-5,494	-2,779	-4,289
Exchange Rate Effect	-23	-122	-70	71	-16
Net Cash Flow	-2,986	83	2,961	2,978	16
Free Cash Flow	5,059	7,804	8,648	5,724	4,498
Free Cash Flow Growth	-35.17%	-9.76%	51.08%	27.26%	-8.32%
Free Cash Flow Margin	12.61%	17.88%	20.08%	16.54%	14.10%
Free Cash Flow Per Share	2.91	4.45	4.87	3.23	2.54

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).